AstraZeneca Results Presentation Deck

2021 and beyond: the acquisition of Alexion Accelerating the strategic and financial development Compelling scientific complementarity and synergy Increased immunology presence: complement system platform, currently applied in rare diseases Pipeline boosted with 11 molecules across 20+ programmes Leveraging AstraZeneca's precision-medicine capabilities 25 ● ● Combination of two science- and patient-centric organisations Focus on science and innovation Patient-centric organisations with high-touch patient support services ● ● Further-sustained, industry-leading revenue growth Attractive growth in specialty and highly-specialised/rare-disease care Leverage AstraZeneca's global geographical reach to accelerate Alexion medicines Double-digit average annual revenue growth through 2025 ● Improved profitability and strengthened cash flow Core operating margin significantly enhanced in the short term, and with continued margin expansion thereafter Synergies c.$500m per year by the end of the third year following completion Double-digit percentage core EPS accretion anticipated in the first three years following completion Strong cash flow, rapid debt deleveraging with an ambition to increase the dividend Strong, investment-grade credit rating to provide strategic and financial flexibility Source: 12 December 2020 webinar and conference call for investors and analysts on the proposed Alexion acquisition. Targets provided above are aspirational only and should not be considered formal guidance. For details, including legal disclaimer, please visit: https://www.astrazeneca.com/investor-relations/astrazeneca-to-acquire-alexion.html. B ● ● ●

View entire presentation